Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy

Annals of Oncology

Volumn 23, Issue 10, 2012, Pages 2681-2686

  Terpos, E ^a   Kastritis, E ^a   Christoulas, D ^a   Gkotzamanidou, M ^a   Eleutherakis Papaiakovou, E ^a   Kanellias, N ^a   Papatheodorou, A ^a   Dimopoulos, M A ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Activin A; Bone disease; Lenalidomide; Multiple myeloma; Survival

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ACTIVIN A; ALKALINE PHOSPHATASE BONE ISOENZYME; BORTEZOMIB; CARBOXY TERMINAL TELOPEPTIDE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; LENALIDOMIDE; MELPHALAN; OSTEOCALCIN; PREDNISONE; THALIDOMIDE; ZOLEDRONIC ACID;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE DISEASE; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG MEGADOSE; FEMALE; GAMMOPATHY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; OSTEOLYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; STEROID THERAPY; SURVIVAL RATE; TREATMENT RESPONSE;

ACTIVINS; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BONE AND BONES; CASE-CONTROL STUDIES; DEXAMETHASONE; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; SURVIVAL RATE; THALIDOMIDE;

EID: 84867135322     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds068     Document Type: Article

References (15)

1. Luisi S, Florio P, Reis FM, Petraglia F. Expression and secretion of activin A: possible physiological and clinical implications. Eur J Endocrinol 2001; 145: 225-236.
2. Hedger MP, Winnall WR, Phillips DJ, de Kretser DM. The regulation and functions of activin and follistatin in inflammation and immunity. Vitam Horm 2011; 85: 255-297.
3. Kawabata N, Kamiya N, Suzuki N et al. Changes in extracellular activin A:follistatin ratio during differentiation of a mesenchymal progenitor cell line, ROB-C26 into osteoblasts and adipocytes. Life Sci 2007; 81: 8-18.
4. Fuller K, Bayley KE, Chambers TJ. Activin A is an essential cofactor for osteoclast induction. Biochem Biophys Res Commun 2000; 268: 2-7.
5. Eijken M, Swagemakers S, Koedam M et al. The activin A-follistatin system: potent regulator of human extracellular matrix mineralization. FASEB J 2007; 21: 2949-2960.
6. Leto G. Activin A and bone metastases. J Cell Physiol 2010; 225: 302-309.
7. Leto G, Incorvaia L, Badalamenti G et al. Activin A circulating levels in patients with bone metastasis from breast or prostate cancer. Clin Exp Metastasis 2006; 23: 117-122.
8. Terpos E, Moulopoulos LA, Dimopoulos MA. Advances in imaging and the management of myeloma bone disease. J Clin Oncol 2011; 29: 1907-1915.
9. Vallet S, Mukherjee S, Vaghela N et al. Activin A promotes multiple myelomainduced osteolysis and is a promising target for myeloma bone disease. Proc Natl Acad Sci USA 2010; 107: 5124-5129.
10. Dimopoulos MA, Terpos E. Lenalidomide: an update on evidence from clinical trials. Blood Rev 2010; 24(Suppl 1):S21-S26.
11. Vallet S, Patel K, Cirstea D et al. Lenalidomide in combination with the activin receptor type II murine Fc protein RAP-011: preclinical rationale for a novel antimyeloma strategy. Blood (ASH Annual Meeting Abstracts) 2010; 116: (Abstr 4075).
12. Dimopoulos MA, Palumbo A, Attal M et al. Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement. Leukemia 2011; 25: 749-760.
13. Terpos E, Mihou D, Szydlo R et al. The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio. Leukemia 2005; 19: 1969-1976.
14. Chantry AD, Heath D, Mulivor AW et al. Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo. J Bone Miner Res 2010; 25: 2633-2646.
15. Christoulas D, Dimopoulos M, Katodritou E et al. The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation. Haematologica 2010; 95 Suppl 2: 397. [EHA Annual Meeting] (Abstr 0958).